Bouin Mickaël, Aoust Louise D'
Centre de recherche, Hôpital Saint-Luc, Centre hospitalier de l'Université de Montréal, Québec, Canada.
Gastroenterol Clin Biol. 2002 Oct;26(10):926-9.
Glucagonomas are rare tumors originating in alpha-cells of the pancreas. The most common clinical presentation is the association of diabetes mellitus, necrolytic erythema, weight loss and anemia. The diagnosis of pancreatic tumor is usually made by abdominal computed tomography and/or endoscopic ultrasonography. Indium-labeled octreotide scanning is useful for the localization of most neuroendocrine tumors and their metastases. Glucagon release can be confirmed by a high concentration of plasma glucagon. We report the case of a 74-year-old patient who had a glucagonoma with particular presentation of neurological impairment and weight loss. The diagnosis was confirmed by usual imaging procedures and plasma glucagon level. Medical treatment was started with long-acting repeatable octreotide (Sandostatin(R) LAR). After a one-year follow-up, the patient remained well. The original presentation and benefit of a new, long-acting somatostatin analog for the treatment of inoperable glucagonoma are discussed.
胰高血糖素瘤是起源于胰腺α细胞的罕见肿瘤。最常见的临床表现是糖尿病、坏死性红斑、体重减轻和贫血。胰腺肿瘤的诊断通常通过腹部计算机断层扫描和/或内镜超声检查来进行。铟标记的奥曲肽扫描对大多数神经内分泌肿瘤及其转移灶的定位很有用。血浆胰高血糖素浓度升高可证实胰高血糖素的释放。我们报告了一例74岁患有胰高血糖素瘤的患者，其具有神经功能障碍和体重减轻的特殊表现。通过常规影像学检查和血浆胰高血糖素水平确诊。开始使用长效可重复注射的奥曲肽（善龙）进行药物治疗。经过一年的随访，患者情况良好。讨论了一种新型长效生长抑素类似物治疗无法手术切除的胰高血糖素瘤的原始表现和疗效。
